VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jeff lipschutz who wrote (12274)	7/30/1998 3:47:00 PM
From: VLAD	Read Replies (3) of 23519

jeff, You know little of what you write. At $10.00/share Vivus would be selling for less than it costs to get a drug FDA approved and on the market. Add the cost of the new production facility, the patented delivery system and ALIBRA and any other R&D in progress not to mention the good will or earnings potential and $17.00/share is a bargain for any large pharma with an effective marketing team. The management ruined this company and not the product. Vivus is a good deal right now in a red hot ED market. The question is how low is Vivus willing to sell out for. I think anything under 15 is a joke and anything over 18 is reasonable.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next